System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40290752 DOI: 10.1039/d5ra00484e

Semi-synthesis and biological activities of heterocyclic compounds containing camphor.

RSC Adv 15(17):13199-13213

Authors: Zeinab S Hamza, Wael N Hozzein, Khaled El-Adl, Mohammad K Okla, Gehad AbdElgayed, Wael A A Fadaly, Hussein S Mohamed

Affiliations

  • Chemistry of Medicinal and Aromatic Plants Department, Research Institute of Medicinal and Aromatic Plants (RIMAB), Beni-Suef University Beni-Suef 62511 Egypt +201000800296.
  • Botany and Microbiology Department, Faculty of Science, Beni-Suef University Beni-Suef Egypt.
  • Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development Cairo Egypt.
  • Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Nasr City 11884 Cairo Egypt.
  • Botany and Microbiology Department, College of Science, King Saud University P.O. Box 2455 Riyadh 11451 Saudi Arabia.
  • Integrated Molecular Plant Physiology Research, Department of Biology, University of Antwerp Antwerp 2020 Belgium.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University Beni-Suef Egypt.

Abstract

Breast cancer and lung cancer are two of the most prevalent and deadly malignancies worldwide. Both cancers present significant challenges in terms of effective treatment and management, highlighting the urgent need for novel therapeutic strategies that can improve patient outcomes. This study focuses on the synthesis of novel heterocyclic compounds derived from the naturally formed camphor, aimed at evaluating their cytotoxicity. The research addresses the need for effective cancer treatments by presenting compounds that demonstrate significant inhibitory effects against MCF-7 breast carcinoma cells. Among these, compound 20 exhibited remarkable potency, with an IC value of 0.78 μM, surpassing the efficacy of standard chemotherapeutics, dasatinib (IC = 7.99 μM) and doxorubicin (IC = 3.10 μM). In the context of A549 lung cancer cells, compound 20 also showed strong inhibitory activity (IC = 1.69 μM), again outperforming dasatinib (IC = 11.8 μM) and doxorubicin (IC = 2.43 μM). To further elucidate the biological activities of these compounds, molecular docking studies were performed, revealing that compound 20 exhibited the highest binding energy among the tested compounds, supporting the experimental findings. These results indicate that the synthesized camphor-derived heterocycles, particularly compound 20, have significant potential as potent anticancer agents against breast and lung cancer cell lines.

MeSH

Cells, Lung, Dasatinib, Breast Neoplasms, Doxorubicin, Neoplasms, Heterocyclic Compounds, Camphor, Lung Neoplasms, Breast, Therapeutics